Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to confirm this finding. A combination of transarterial chemoembolization ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo. PH284, an investigational pherine nasal spray, showed improvements in the ...

Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer. The FDA granted approval to datopotamab ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes. Drug toxicity was the most ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.